Skip to main content
OpenTrials
Completed

NCT Number: NCT04773028

The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kartal Kosuyolu High Speciality Training and Research Hospital

Istanbul, Eyalet/Yerleşke, 34800, Turkey (Türkiye)

About this study

Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery. Only 4% of patients with acute pulmonary embolism develop chronic thromboembolic pulmonary hypertension and acute pulmonary embolism or deep vein thrombosis is reported in the anamnesis of 75% of those with chronic thromboembolic disease. Therefore, the etiology of the disease is not clear. Altought many studies are done, especially the role of inflamation is emhasised underlie the disease.

Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension.

Matrix metalloprotinase enzymes are known to play a role in atherosclerosis. This research will investigate whether there is atherosclerosis together with inflamattion in the background of chronic thromboembolic hypertension.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Despite 3 months of anticoagulation therapy
  • mean pulmonary arterial pressure > 20 mmHg
  • pulmonary vasculary resistance > 3 wood
  • pulmonary capillary wedge pressure < 15 mmHg
  • perfusion defect in ventilation perfusion scintigraphy
  • pulmonary angiography or computed tomography angiography showing pulmonary artery occlusive lesions

Exclusion criteria

  • Patients undergoing pulmonary thromboendarterectomy concomitant coronary bypass, carotid endarterectomy, aortic valve, ascending aorta, mitral valve, tricuspid valve, pulmonary valve surgery
  • Patients who have undergone surgical or percutaneous procedures due to atherosclerotic disease

Treatment and study plan

matrix metalloproteinase enzymes 2 and 9

Other

concentration of matrix metalloproteinase 2 and 9 enzymes

Primary outcomes

  1. Concentration of Matrix Metalloproteinase 2 and 9 Enzymes

    Time frame: 1 year

    Measurement the concentration of matrix metalloproteinase 2 and 9 enzymes by elisa and western blot techniques.

Sponsors and collaborators

Lead sponsor

AHMET ZENGIN

Other Gov

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Feb 26, 2021
Registry last updated
Aug 10, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.